Monday, 20 January 2020
The first full day of the Congress, open to Industry and Standard ticket holders, focuses on the latest in EB research – including current challenges, therapeutics, and a clinical trial update. For any queries related to the programme, please email programme@ebworldcongress.org. Please note: The Congress programme is updated monthly and the current version is, therefore, subject to change.Programme overview
08:30 | WELCOME
Chairs: Jemima Mellerio & Jouni Uitto
Chairs: Jemima Mellerio & Jouni Uitto
Challenges and unmet needs – the breadth of preclinical work ongoing
Jouni Uitto
Jouni Uitto
08:40 | CLASSIFICATION
Chair: Jo-David Fine
Chair: Jo-David Fine
EB classification and updates from the 2019 classification meeting
Cristina Has
Cristina Has
08:55 | CURRENT DILEMMAS – A CONGRESS DEBATE (The complexity of EB)
Chair: Jo-David Fine
Chair: Jo-David Fine
EB as a systemic disease – implications for research
Johann Bauer Modelling EB in the research environment
Leena Bruckner-Tuderman Curative vs disease modifying strategies
Jakub Tolar Open debate – how to focus research in EB; avoid being spread too thinly because of complexity; where and how to direct the research; is prioritisation possible or feasible
Johann Bauer Modelling EB in the research environment
Leena Bruckner-Tuderman Curative vs disease modifying strategies
Jakub Tolar Open debate – how to focus research in EB; avoid being spread too thinly because of complexity; where and how to direct the research; is prioritisation possible or feasible
09:30 | COFFEE BREAK
10:00 | THE CHALLENGES OF EB SKIN
Chair: Peter Marinkovich
Chair: Peter Marinkovich
Wound healing mechanisms – macrophages
Sabine Eming Immune function and bacterial challenge
Josefine Hirschfeld Clinical research
Maria Jose Escamez Learnings from other diseases (cell inflammation)
David Abraham Panel discussion
Sabine Eming Immune function and bacterial challenge
Josefine Hirschfeld Clinical research
Maria Jose Escamez Learnings from other diseases (cell inflammation)
David Abraham Panel discussion
11:05 | INFLAMMATION, FIBROSIS, & THERAPEUTICS
Chair: Leena Bruckner-Tuderman
Chair: Leena Bruckner-Tuderman
Fibrosis in EB – mechanisms and anti-fibrotic strategies
Alexander Nyström Losartan for RDEB trial – results and international perspectives
Dimitra Kiritsi miRNA in EB
Giovanna Zambruno Panel discussion Oral presentations 112 - Esteban Chacon-Solano
Novel players in the establishment and progression of fibrosis in recessive dystrophic epidermolysis bullosa 25 - Liat Samuelov
Skin microbiome characteristics of dystrophic epidermolysis bullosa patient
Alexander Nyström Losartan for RDEB trial – results and international perspectives
Dimitra Kiritsi miRNA in EB
Giovanna Zambruno Panel discussion Oral presentations 112 - Esteban Chacon-Solano
Novel players in the establishment and progression of fibrosis in recessive dystrophic epidermolysis bullosa 25 - Liat Samuelov
Skin microbiome characteristics of dystrophic epidermolysis bullosa patient
12:25 | LUNCH
13:25 | CANCER & CANCER THERAPEUTICS
Chair: Johann Bauer
Chair: Johann Bauer
KEYNOTE: Precision medicine for SCC
Kevin Harrington Genetic overview/current RDEB knowledge
Andy South Interdisciplinary management and therapies for EB associated cancers (skin, mucosal, internal)
Leena Bruckner-Tuderman RDEB-SCC protocols (rigosertib, pembrolizumab, cetuximab, & nivolumab, SCC cream)
Jemima Mellerio Panel discussion Oral presentations 73 - Angela Filoni
Morphological and morphometrical analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a prospective study 128 - Jasbani Dayal
Heterogeneous addiction to TGFβ signalling in life threatening cutaneous squamous cell carcinomas arising in recessive dystrophic epidermolysis bullosa
Kevin Harrington Genetic overview/current RDEB knowledge
Andy South Interdisciplinary management and therapies for EB associated cancers (skin, mucosal, internal)
Leena Bruckner-Tuderman RDEB-SCC protocols (rigosertib, pembrolizumab, cetuximab, & nivolumab, SCC cream)
Jemima Mellerio Panel discussion Oral presentations 73 - Angela Filoni
Morphological and morphometrical analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a prospective study 128 - Jasbani Dayal
Heterogeneous addiction to TGFβ signalling in life threatening cutaneous squamous cell carcinomas arising in recessive dystrophic epidermolysis bullosa
15:10 | TEA BREAK
15:40 | THERAPEUTICS
Chair: Jouni Uitto
Chair: Jouni Uitto
EBS target and treatment options/targeting EB as an inflammatory disease
Thomas Magin Read-through therapeutics: drug re-purposing for EB patients
David Woodley Topical treatments – an update
Dedee Murrell
Thomas Magin Read-through therapeutics: drug re-purposing for EB patients
David Woodley Topical treatments – an update
Dedee Murrell
16:20 | NATURAL HISTORY – IMPLICATIONS FOR CLINICAL TRIAL DESIGN
Chair: Jouni Uitto
Chair: Jouni Uitto
PEBLES
Jemima Mellerio The EB clinical characterisation and outcomes database
Anna Bruckner Discussion
Jemima Mellerio The EB clinical characterisation and outcomes database
Anna Bruckner Discussion
16:55 | CLOSE